On the other hand, a synthetic FFAR4 agonist GSK 137647 (administered at the dose of 1 mg/kg BW, i.p., twice daily) alleviated DSS-induced intestinal inflammation in mice, as indicated by significantly reduced MPO activity and macroscopic parameters, such as BW loss [28]. Here, FFAR4 is linked to inflammation.